The Cost-Effective Evaluation on TCM Combined with Nucleoside (acid) Analogues in the Treatment of Chronic Hepatitis
Article Sidebar
Main Article Content
บทคัดย่อ
This research objective was designed to evaluate the economic efficiency of traditional Chinese medicine-combined nucleoside, nucleotide analogue therapy for patients with chronic hepatitis B as compared with that of nucleoside, nucleotide analogue therapy. Method: The electronic patient record database of the First Affiliated Hospital of Guangxi University of Chinese Medicine was taken as data source, and the medical data from all patients diagnosed with chronic hepatitis B from January 2018 to December 2022 were collected retrospectively. Those patients were divided, upon difference in their therapeutic regimens, into the antiviral treatment group by Western medicine and the treatment group integrating both Chinese and Western medicine. A Markov model was constructed so as to emulate the progression in chronic hepatitis B. Costs of illness and quality-adjusted life years (QALY) were calculated among patients receiving different therapeutic regimens. Teeage pro was adopted for both cost-utility analysis and sensitivity analysis on both therapeutic regimens. Results: Compared with the antiviral treatment by Western medicine, patients with chronic hepatitis B receiving the regimen integrating Chinese and Western medicine obtained higher medical bills while gaining more QALYs, with an incremental cost-effectiveness ratio of CNY 79238.96 yuan/QALY; such figure was less than 3 times the per capita GDP of Nanning City. Conclusion: The addition of traditional Chinese medicine therapy to the antiviral therapy for patients with chronic hepatitis B generates certain pharmaco-economic advantages.
Article Details
References
Bai Jiameng & Liu Guangwei. (2022). Clinical Research on Treating Cirrhotic Ascites by Acupuncture in Combination with Tuihuang Mixture Enema. Acupuncture Research. 47 (01), 59-64.
Chen Jing, Xu Lei & Cao Zhengmin. (2022). Advances in Molecular Mechanisms on Traditional Chinese Medicine against Hepatic Fibrosis. China Journal of Traditional Chinese Medicine and Pharmacy. 37 (03), 1564-1569.
Collaborators, G. C. (2020). The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. Gastroenterology & Hepatology. 5 (3), 245-266.
Collaborators, P. O. (2023). Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study. The Lancet. Gastroenterology & Hepatology. 8, 879–907.
China Guidelines for Pharmaco-economic Evaluations 2020. (2020). In (Vol. T/CPHARMA 003-2020): Chinese Pharmaceutical Association.
Dan, Y. Y., Wong, J. B., Hamid, S. S. (2014). Consensus cost-effectiveness model for treatment of chronic hepatitis B in Asia Pacific countries. Hepatology International. 8 (3), 382-394.
Fei, B., Dai, W., & Zhao, S. (2018). Efficacy, Safety, and Cost of Therapy of the Traditional Chinese Medicine, Catalpol, in Patients Following Surgical Resection for Locally Advanced Colon Cancer. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 24, 3184-3192.
Feng Zhigang, Li Tao & Zhao BQ. (2022). Efficacy of Compound Biejia Ruangan Tablets in Combination with Entecavir on Patients with Decompensated Hepatitis B Cirrhosis, Liver Functionality and Immune Functionality. Chinese Archives of Traditional Chinese Medicine. 40 (01), 184-187.
Ge, F., Yang, Y., Bai, Z. (2023). The role of Traditional Chinese medicine in anti-HBV: background, progress, and challenges. Chinese Medicine. 18 (1).
Guo Xiaojie, Guo Yanlin & Zhang Shuquan. (2020). Health-economic Evaluation of Bushen Zhuyu Huatan Prescription in Treating Hypertensive Cerebral Hemorrhage. Guangming Journal of Chinese Medicine. 35 (14), 2170-2172.
Han, Z., Nie, H., Huang, Z. (2023). Differences in medical costs between TCM users and TCM nonusers in inpatients with thalassemia. BMC Health Serv Res. 23 (1), 635.
Hsu, Y. C., Huang, D. Q., & Nguyen, M. H. (2023). Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nature Reviews. Gastroenterology & Hepatology. 20 (8), 524-537.
Jiang Xin, Jiang Ying & Li Xiuyun. (2021). Clinical Observation of 30 Cases of Cirrhosis Ascites Treated by External Acupoint Application of Jiaomouxishui Paste in Combination with Western Medicine Therapy. Hunan Journal of Traditional Chinese Medicine. 37 (09), 74-77.
J, T. D., E, R. R., J, B. C. (2009). Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. %J Hepatology (Baltimore, Md.). 49 (5), 1503-1514.
Xiao, H.-M., Shi, M.-J., Jiang, J.-M. (2022). Efficacy and safety of AnluoHuaxian pills on chronic hepatitis B with normal or minimally elevated alanine transaminase and early liver fibrosis: A randomized controlled trial. Journal of Ethnopharmacology. 293.
Xing, Y., Zhong, W., Peng, D. (2023). Chinese herbal formula ruangan granule enhances the efficacy of entecavir to reverse advanced liver fibrosis/early cirrhosis in patients with chronic HBV infection: A multicenter, randomized clinical trial. Pharmacological Research, 190.
Xuan, J., Huang, M., Lu, Y. (2018). Economic Evaluation of Safflower Yellow Injection for the Treatment of Patients with Stable Angina Pectoris in China: A Cost-Effectiveness Analysis. Altern Complement Med. 24 (6), 564-569. doi:10.1089/acm.2017.0284
Xia Kebiao, Zheng Wei & Wang Yangping. (2022). Observation of Efficacy of Anluo Huayxian Pills in Combination with Adefovir Dipivoxil on Hepatitis B Cirrhosis. Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine. 22 (22), 11-13+17.
Qian Xiaolu, You Yanli & Shu Shi. (2015). Health-economic Evaluation of Rongnao Xingshen Acupuncture in Treating Post-stroke Depression. Journal of Zhejiang Chinese Medicine University. 39 (09), 700-703.
Qiu Youru, Huan Na & Deng Jie. (2021). Health-economic Analysis of Acupuncture and Traditional Chinese Medicine Combination Therapy for Stroke. Chinese Manipulation and Rehabilitation Medicine. 12 (07), 75-78.
Shi Weiqun. (2013). An Idea with Equal Attention to both Antiviral and Anti-fibrosis Therapies. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases. 23 (05), 257-258+264.
Yu, S., Zhang, Y., Yao, Y. (2020). Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database. J Headache Pain. 21 (1), 53.
Yu, X., Gao, Y., Zhang, X. (2024). Hepatitis B: Model Systems and Therapeutic Approaches. Journal of Immunology Research, 1-15.
You Hong, Wang Fusheng & Li Taisheng. (2023). Chronic hepatitis B Prevention Guide (2022 Edition). Journal of Practical Hepatology. 26 (03), 457-478.
Yu Jia & Xie Yanming. (2006). Research Idea and Method for Health-economic Evaluation of Traditional Chinese Medicine. Chinese Journal of Information on Traditional Chinese Medicine. (06), 106-108.
Zhang Wenfu & Wang Zhenchang. (2022). Research on Molecular Mechanisms of Traditional Chinese Medicine Therapy for Hepatic Fibrosis. [J]. Chinese Archives of Traditional Chinese Medicine. 40 (12), 119-124.
Zhang, T., Liang, Z., Lin, T. (2022). Cost-effectiveness of folic acid therapy for primary prevention of stroke in patients with hypertension. BMC Medicine. 20 (1), 407.